Scholar Rock (SRRK) experienced a 4.6% decline in its stock price to $52.87 on Monday afternoon, marking the first full trading session after the U.S. Food and Drug Administration (FDA) approved its lead drug, Isembyld (apitegromab-mstn). The approval, announced after Friday's market close, clears the path for the company's first commercial product, but it also transitions the investment thesis from a binary regulatory event to a more complex commercial challenge.
The FDA's decision covers adults and children aged 2 and older with spinal muscular atrophy (SMA) who are already receiving an SMN2-targeted therapy. Isembyld is distinguished as the first approved SMA treatment that directly targets muscle loss, making it an add-on therapy rather than a replacement for existing treatments. This novel mechanism could broaden its appeal, but it also means the drug must compete for mindshare and reimbursement alongside established therapies.
The pivotal trial data underpinning the approval showed a 2.2-point improvement on the Hammersmith Functional Motor Scale-Expanded (HFMSE) after one year for the recommended 10 mg/kg dose, compared to placebo. In the main efficacy population of 103 patients aged 2 to 12, 34.2% of treated patients achieved at least a three-point gain, versus 13.5% on placebo. All participants remained on an approved SMN2-directed therapy, underscoring the drug's role as an adjunct.
Safety and logistics now become the primary focus. Fractures were reported in 9% of patients at the recommended dose, compared to 2% on placebo. The drug is administered via intravenous infusion every four weeks, which requires coordination among physicians, treatment centers, and insurers. Scholar Rock stated that product shipments would begin within days and that it is already engaging with commercial and government payers. The company's announcement estimates that roughly 35,000 people worldwide have received an SMN-targeted treatment, but the number of immediate U.S. candidates remains unclear.
Investors are wary of a slow launch. Scholar Rock's market capitalization stood near $6.44 billion on Monday afternoon, a valuation that appears to price in robust uptake. The company reported no revenue in the June quarter and a net loss of $109.9 million, with combined R&D and SG&A expenses of $108.9 million. These figures include costs for a pre-built commercial organization, setting a high bar for early sales.
Financially, Scholar Rock is not under immediate pressure. The company ended June with $492.1 million in cash, cash equivalents, and marketable securities, including $62.8 million raised through its at-the-market program during the quarter. Additionally, the approval came with a rare pediatric disease priority review voucher, which could be monetized or used for future applications.
The bullish case remains intact: the label includes adults and children, the mechanism is unique, and 98% of treated SAPPHIRE participants opted to continue into the long-term extension study. However, the commercial counterargument is strong. Payers must accept another therapy on top of existing treatment, monthly infusions add friction, and the company has yet to disclose launch metrics that justify its multibillion-dollar valuation.
Monday's decline does not negate the approval; it raises the bar for execution. Initial payer coverage, prescription volumes, infusion starts, and the first reported product revenue will now be scrutinized more heavily than regulatory milestones. A smooth launch could make the broad label economically meaningful, while delays or weak uptake would expose how much of the stock's value was already priced in before the first vial shipped.
